We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+4.91%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$12B
AUM Growth
+$251M
Cap. Flow
-$39.8M
Cap. Flow %
-0.33%
Top 10 Hldgs %
36.53%
Holding
164
New
29
Increased
43
Reduced
30
Closed
27

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$255M
2
BSX icon
Boston Scientific
BSX
+$146M
3
ABBV icon
AbbVie
ABBV
+$121M
4
AGN.PRA
Allergan plc
AGN.PRA
+$109M
5
PBYI icon
Puma Biotechnology
PBYI
+$103M

Top Sells

Rank Stock Value
1
PRGO icon
Perrigo
PRGO
+$207M
2
ZBH icon
Zimmer Biomet
ZBH
+$116M
3
MDVN
MEDIVATION, INC.
MDVN
+$115M
4
ACT.PRA
ACTAVIS PLC Pfd Conv Ser A (Irl)
ACT.PRA
+$105M
5
SYK icon
Stryker
SYK
+$87.8M

Sector Composition

Rank Sector Weight
1 Healthcare 86.53%
2 Financials 0.24%
3 Technology 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CEMP
126
DELISTED
Cempra, Inc.
CEMP
$1.72M 0.01%
50,000
– –
XTNT icon
127
Xtant Medical Holdings
XTNT
$57.8M
$1.66M 0.01%
39,620
– –
CGNT
128
DELISTED
Cogentix Medical, Inc.
CGNT
$1.6M 0.01%
+990,745
New +$1.62M
IMUX icon
129
PUT
Immunic
IMUX
$177M
$1.58M 0.01%
188
– –
AMRN
130
Amarin Corp
AMRN
$298M
$861K 0.01%
17,500
– –
ADVM
131
DELISTED
Adverum Biotechnologies
ADVM
– –
-28,390
Closed -$9.58M
BAX icon
132
Baxter International
BAX
$12.8B
– –
-526,894
Closed -$19.6M
CLDX icon
133
Celldex Therapeutics
CLDX
$2.95B
– –
-40,000
Closed -$16.7M
CRIS icon
134
Curis
CRIS
$9.69M
– –
-362
Closed -$1.74M
DVA icon
135
DaVita
DVA
$15.5B
– –
-76,000
Closed -$6.18M
MDT icon
136
PUT
Medtronic
MDT
$112B
– –
-695,707
Closed -$54.3M
MDXG icon
137
MiMedx Group
MDXG
$629M
– –
-836,800
Closed -$8.7M
PBYI icon
138
CALL
Puma Biotechnology
PBYI
$397M
– –
-50,000
Closed -$11.8M
PCRX icon
139
Pacira BioSciences
PCRX
$1.04B
– –
-176,000
Closed -$15.6M
PRGO icon
140
Perrigo
PRGO
$1.44B
– –
-1,247,800
Closed -$207M
SNN icon
141
CALL
Smith & Nephew
SNN
$13.8B
– –
-100,000
Closed -$3.42M
SUPN icon
142
Supernus Pharmaceuticals
SUPN
$2.7B
– –
-580,000
Closed -$7.01M
TCRT icon
143
Alaunos Therapeutics
TCRT
$4.64M
– –
-16,918
Closed -$27.3M
VTRS icon
144
PUT
Viatris
VTRS
$20.8B
– –
-225,000
Closed -$13.4M
LUMO
145
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-54,811
Closed -$27M
AMAG
146
DELISTED
AMAG Pharmaceuticals
AMAG
– –
-275,000
Closed -$15M
AKRX
147
CALL
DELISTED
Akorn Inc
AKRX
– –
-50,000
Closed -$2.38M
ACHN
148
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-158,000
Closed -$1.56M
ARQL
149
DELISTED
Arqule Inc
ARQL
– –
-4,896,108
Closed -$11M
QLTI
150
CALL
DELISTED
QLT Inc
QLTI
– –
-500,000
Closed -$1.96M
3 4 5
6
7

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q2 2015 Portfolio in Review

As of Q2 2015, OrbiMed held 164 positions worth $12B, up 2.1% from $11.7B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

OrbiMed's Q2 2015 filing shows 29 new, 43 increased, 30 reduced and 27 closed positions. Its largest new stake was Allergan plc: 104,200 shares worth $109M. The largest sale was Perrigo, an estimated $207M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 83% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q2 2015 buy was Allergan plc: 104,200 shares worth $109M.
  • OrbiMed added most to Alexion Pharmaceuticals in Q2 2015, an estimated $255M increase.
  • OrbiMed's biggest Q2 2015 reduction was Zimmer Biomet, cutting an estimated $116M.
  • OrbiMed fully exited Perrigo in Q2 2015, selling an estimated $207M.
  • OrbiMed's ten largest holdings make up 37% of its $12B portfolio in Q2 2015.
  • OrbiMed opened 29 new positions and closed 27 in Q2 2015.
  • OrbiMed's portfolio value rose 2.1% quarter-over-quarter to $12B.

Based on OrbiMed's 13F filing for Q2 2015, filed 14 Aug 2015.